We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Monoclonal Antibodies from Tobacco Plants

By Biotechdaily staff writers
Posted on 27 Jul 2006
Print article
Researchers are using tobacco plants to produce cancer-fighting monoclonal antibodies that recognize and hunt down breast and colorectal cancer cells.

While therapeutic applications for such antibodies continue to grow at a fast rate, production cannot keep pace. Hilary Koprowski, M.D., a virologist and professor of cancer biology at Jefferson Medical College of Thomas Jefferson University and Jefferson's Kimmel Cancer Center (Philadelphia, USA), argued that "plants are safer, less expensive, and easier to use” than currently used methods in the laboratory and with animals. For mass production purposes, he stated, "plants make more sense.” He and coworkers reported their findings in the May 23, 2006, issue of the journal Proceedings of the [U.S.] National Academy of Sciences.

In the most recent studies, Dr. Koprowski and his team inserted DNA coding for an antibody against the Lewis Y antigen, which is found on breast and colorectal cancer cells, among other cancers, into tobacco plants. The plants then become factories generating antibodies. As in earlier studies, the antibodies were able to kill the cancer cells in the laboratory and suppressed tumor growth in mice. Not only that, these plant-made antibodies performed as well as those produced in the conventional way, by mammalian cells. Both types of antibodies suppressed tumor cell growth in mice up to 28 days.

This study produced an added surprise, which has not been shown before: the researchers demonstrated that the antibodies attached to the human Fc receptor, a major step in the development of immunotherapy. So-called effector cells--tumor-cell killing macrophages--recognize monoclonal antibodies through their Fc receptors.

"This technology has all the potential in the world,” Dr. Koprowski said, adding that clinical trials involving plant-produced antibodies should be planned. "It will be the future, and in the next five to 10 years, it could be the main way that therapeutic antibodies are made.”



Related Links:
Jefferson's Kimmel Cancer Center
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: A one-step confirmatory laboratory test could definitively diagnose active syphilis infection within 10 minutes (Photo courtesy of Adobe Stock)

First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes

In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.